Skip to Content
Living with hypothyroidism? Explore treatment options >>

Caprelsa (vandetanib) Disease Interactions

There are 10 disease interactions with Caprelsa (vandetanib):

Moderate

Multikinase Inhibitors (Includes Caprelsa) ↔ Lung Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Interstitial Pneumonitis, Pulmonary Impairment

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.

Moderate

Vandetanib (Includes Caprelsa) ↔ Heart Failure

Moderate Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure

Heart failure, including fatalities have occurred in patients treated with vandetanib. Monitor for signs and symptoms of heart failure. Consider discontinuation of therapy in patients with heart failure. Close monitoring is recommended.

Moderate

Vandetanib (Includes Caprelsa) ↔ Hemorrhage

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding

Serious hemorrhagic events, including fatalities, have occurred in patients treated with vandetanib. Do not administer vandetanib to patients with a recent history of hemoptysis of >= 1/2 teaspoon of red blood. Discontinue treatment in patients with severe hemorrhage.

Moderate

Vandetanib (Includes Caprelsa) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of vandetanib is not recommended for patients with moderate and severe hepatic impairment, as the safety and efficacy of this agent have not been established.

Moderate

Vandetanib (Includes Caprelsa) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

Hypertension, including hypertensive crisis, has occurred in patients treated with vandetanib. Monitor all patients for hypertension and a dose reduction or interruption may be necessary. If hypertension cannot be controlled, do not resume vandetanib. Care should be taken when using this agent in hypertensive patients. Close monitoring is recommended.

Moderate

Vandetanib (Includes Caprelsa) ↔ Hypothyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism

Increased dosing of thyroid replacement therapy was required in patients with a prior thyroidectomy. It is recommended to obtain Thyroid-stimulating hormone (TSH) at baseline, during therapy and thereafter as clinically indicated. If signs or symptoms of hypothyroidism occur, examine thyroid hormone levels and adjust thyroid replacement therapy accordingly.

Moderate

Vandetanib (Includes Caprelsa) ↔ Ischemic Attack

Moderate Potential Hazard, Moderate plausibility

Applies to: Ischemic Heart Disease

Ischemic cerebrovascular events, including fatalities, occurred in patients treated with vandetanib. The safety of resumption of vandetanib therapy after resolution of an ischemic cerebrovascular event has not been studied. Care should be taken when prescribing this agent to patients at risk. Discontinue treatment in patients who experience a severe ischemic cerebrovascular event.

Moderate

Vandetanib (Includes Caprelsa) ↔ Qt Prolongation

Moderate Potential Hazard, Moderate plausibility

Applies to: Arrhythmias, Electrolyte Abnormalities

Vandetanib can prolong the QT interval, and its use is contraindicated in patients with congenital long QT syndrome. Additionally, vandetanib should not be used in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Care should be exercised when using this agent in patients with ventricular arrhythmias or recent myocardial infarction. It is recommended to correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to starting therapy with vandetanib. Obtain an ECG and serum potassium, calcium, magnesium and TSH at baseline, during treatment, and frequently as necessary.

Moderate

Vandetanib (Includes Caprelsa) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Vandetanib exposure is increased in patients with impaired renal function. It is recommended to reduce the starting dose in patients with moderate to severe renal impairment and monitor the QT interval closely. There is no information available for patients with end-stage renal disease requiring dialysis.

Moderate

Vandetanib (Includes Caprelsa) ↔ Rpl Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Posterior Reversible Encephalopathy Syndrome

Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by an MRI of the brain, has occurred in patients treated with vandetanib. Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. It is recommended to discontinue therapy in patients developing RPLS.

Caprelsa (vandetanib) drug Interactions

There are 355 drug interactions with Caprelsa (vandetanib)

Caprelsa (vandetanib) alcohol/food Interactions

There is 1 alcohol/food interaction with Caprelsa (vandetanib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide